Wellington Management Group LLP Has $747.20 Million Stock Holdings in United Therapeutics Corporation $UTHR

Wellington Management Group LLP trimmed its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 39.1% in the second quarter, according to its most recent filing with the SEC. The firm owned 1,379,025 shares of the biotechnology company’s stock after selling 885,222 shares during the period. Wellington Management Group LLP’s holdings in United Therapeutics were worth $747,197,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. BlackRock Inc. bought a new stake in United Therapeutics in the second quarter valued at about $2,868,735,000. Avoro Capital Advisors LLC grew its stake in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the period. AQR Capital Management LLC raised its holdings in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after buying an additional 295,221 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after buying an additional 70,829 shares in the last quarter. Finally, Jupiter Topco LLC bought a new stake in United Therapeutics in the second quarter valued at $450,140,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

Insider Buying and Selling

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,311,581.28. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $541.39, for a total transaction of $5,143,205.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $21,933,333.07. This represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 424,075 shares of company stock worth $227,336,485 over the last quarter. 8.60% of the stock is owned by company insiders.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $515.46 on Friday. United Therapeutics Corporation has a 52 week low of $303.08 and a 52 week high of $609.35. The stock has a market capitalization of $22.11 billion, a PE ratio of 18.44, a PEG ratio of 1.75 and a beta of 0.59. The stock’s fifty day moving average is $530.46 and its 200-day moving average is $538.70.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period in the previous year, the business posted $6.41 earnings per share. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.